Document Detail


Comparison of intraperitoneal and subcutaneous epoetin alfa in peritoneal dialysis patients.
MedLine Citation:
PMID:  10641779     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To compare the efficacy of intraperitoneal (i.p.) and subcutaneous (s.c.) administration of epoetin alfa in patients receiving peritoneal dialysis (PD). DESIGN: A 32-week prospective, randomized, cross-over experimental design. SETTING: Two university-based outpatient PD centers. PATIENTS: Twenty adult PD patients receiving stable doses of s.c. epoetin alfa enrolled in the study. Thirteen patients completed 32 weeks of follow-up. INTERVENTION: Patients were randomly assigned to receive either s.c. or i.p. epoetin alfa at the start of the study. Dose adjustments were made to maintain baseline hematocrit +/- 3 percentage points. Following 16 weeks of treatment, patients crossed over to the other route of administration for an additional 16 weeks. Intraperitoneal epoetin alfa was administered into an empty peritoneal cavity for approximately 8 hours before resuming dialysis. End-of-study i.p. epoetin alfa doses required to maintain target hematocrit were given twice weekly (n = 1), once weekly (n = 11), or once every other week (n = 1). All patients received iron supplements to maintain or exceed prestudy iron parameters. MAIN OUTCOME MEASURE: Prior to the study, the primary outcome measure was defined as the difference in epoetin alfa dose between i.p. and s.c. administration. RESULTS: Thirteen patients completed the study. The area under the dosing-requirement curve for i.p. epoetin alfa was larger than for s.c. administration (p = 0.0029), and the slope of the 16-week dose-requirement curve was greater for i.p. administration (p = 0.017), suggesting greater dose stability for s.c. administration. Paired analysis indicated greater i.p. intrapatient dose requirements (p < 0.0001). The mean difference in s.c. versus i.p. doses was 5000 +/- 1510 units per week. Some patients required escalating i.p. doses to maintain target hematocrit values. Iron administration and iron stores were similar in both groups. CONCLUSION: Intraperitoneal epoetin alfa may be a suitable alternative for some patients for whom s.c. dosing is undesirable. Large i.p. versus s.c. dosing differences noted in a few patients are unexplained, but may result from interpatient variability in i.p. epoetin alfa absorption. Intraperitoneal dosing into an empty peritoneum can be done safely and effectively.
Authors:
C A Johnson; M Wakeen; C A Taylor; S W Zimmerman; J Burkart; A Bhattacharya; M R Kosorok
Related Documents :
6956429 - Pharmacokinetics of methotrexate following intravenous and intraventricular administrat...
1747449 - Thrombopoietic factor enhances murine megakaryopoiesis induced by recombinant erythropo...
18533709 - Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analo...
1386089 - Intramural methotrexate therapy for the prevention of neointimal thickening after ballo...
1432439 - Pharmacokinetics and pharmacodynamics of erythropoietin during therapy in an infant wit...
443429 - Stimulation of iron absorption by polychlorinated aromatic hydrocarbons.
10690559 - Treatment of isografted 9l rat brain tumors with beta-5-o-carboranyl-2'-deoxyuridine ne...
2136809 - Pharmacokinetics of toremifene and its metabolites in patients with advanced breast can...
8585839 - Dose characteristics of a new 300kvp orthovoltage machine.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis     Volume:  19     ISSN:  0896-8608     ISO Abbreviation:  Perit Dial Int     Publication Date:    1999 Nov-Dec
Date Detail:
Created Date:  2000-02-01     Completed Date:  2000-02-01     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  8904033     Medline TA:  Perit Dial Int     Country:  CANADA    
Other Details:
Languages:  eng     Pagination:  578-82     Citation Subset:  IM    
Affiliation:
School of Pharmacy, University of Wisconsin, Madison 53706, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Absorption
Adolescent
Adult
Aged
Area Under Curve
Cross-Over Studies
Epoetin Alfa / administration & dosage*
Female
Ferritins / blood
Follow-Up Studies
Hematinics / administration & dosage*
Hematocrit
Humans
Injections, Intraperitoneal
Injections, Subcutaneous
Iron / therapeutic use
Male
Middle Aged
Peritoneal Dialysis*
Prospective Studies
Safety
Transferrin / analysis
Treatment Outcome
Grant Support
ID/Acronym/Agency:
M01 RR03186/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Hematinics; 11096-37-0/Transferrin; 113427-24-0/Epoetin Alfa; 7439-89-6/Iron; 9007-73-2/Ferritins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Follow-up study of peritoneal fluid kinetics in infants and children on peritoneal dialysis.
Next Document:  HGF: a multifunctional growth factor controlling cell scattering.